NOVN - ノバン （Novan Inc.） ノバンNOVNのチャート
NOVNの企業情報
| symbol | NOVN |
|---|---|
| 会社名 | Novan Inc （ノバン） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 ノーバン(Novan Inc)は後期段階の医薬品会社である。同社は一酸化窒素プラットフォームを使用することによって治療法の開発･商業化に従事する。同社は調整可能な新規化学物質(NCEs)の操作を可能とするNitricil技術によって候補製品を開発する。同社の製剤サイエンスは非活性成分を使用することによって皮膚に応用される時に一酸化窒素の放出のさらなる調整を可能とする。同社は第3相尋常性座瘡の治療用SB204、第2相外生殖器･肛門疣贅の治療用製品候補SB206、皮膚･爪の真菌感染の治療用試験中局所的な抗真菌剤SB208を開発している。同社は炎症性皮膚疾患の治療用SB204を開発している。同社のパイプラインはまた局所的クリーム製品候補SB414を含む。 ノバンは米国の医薬品企業。主に臨床段階で、皮膚科の疾患に対する治療薬の開発・商業化に従事する。皮膚の免疫反応で不可欠な一酸化窒素を用いて治療するプラットフォ―ムを開発し、同社パイプラインには「SB206」、「SB208」、「SB414」などがある。本社はノ―スカロライナ州ダ―ラム。 Novan, Inc. is a clinical development-stage biotechnology company focused on leveraging its proprietary nitric oxide (NO) based technology platform, NITRICIL™ to generate macromolecular New Chemical Entities (NCEs) to treat multiple indications in dermatology, men's and women's health, infectious diseases and gastroenterology conditions with significant unmet needs. The Company's lead product candidate, SB206, a topical antiviral gel, for the treatment of molluscum contagiosum, is currently being evaluated in the B-SIMPLE4 pivotal Phase 3 clinical study. The Company believes that SB206 as a topical, at-home, caregiver-applied therapy with a rapid treatment benefit, if approved, would address an important patient-care need for the treatment of molluscum. |
| 本社所在地 | 4105 Hopson Road Morrisville NC 27560 USA |
| 代表者氏名 | Robert A. Ingram ロバートA.イングラム |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 919-485-8080 |
| 設立年月日 | 38718 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2016年 |
| 従業員数 | 59人 |
| url | www.novan.com |
| nasdaq_url | https://www.nasdaq.com/symbol/novn |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -30.26500 |
| 終値（lastsale） | 2.63 |
| 時価総額（marketcap） | 68486362.46 |
| 時価総額 | 時価総額（百万ドル） 65.23131 |
| 売上高 | 売上高（百万ドル） 2.67800 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 52.27231 |
| 当期純利益 | 当期純利益（百万ドル） -28.42800 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Novan Inc revenues increased 26% to $1.3M. Net loss decreased 40% to $12.8M. Revenues reflect License and collaboration revenue increase of 33% to $1.3M. Lower net loss reflects Change in fair value of warrant increase from $0K to $4.3M (income) General and administrative - Balancing decrease of 28% to $4.8M (expense) Research and Development - Balancing decrease of 10% to $11.8M (expense). |
NOVNのテクニカル分析
NOVNのニュース
Novan, Inc. (NOVN) CEO Paula Stafford on Q2 2022 Results - Earnings Call Transcript 2022/08/12 02:29:11 Seeking Alpha
Novan, Inc. (NASDAQ:NASDAQ:NOVN) Q2 2022 Earnings Conference Call August 11, 2022, 08:30 ET Company Participants Paula Stafford - President, CEO & Chairwoman John Gay - CFO &…
Recap: Novan Q2 Earnings 2022/08/11 13:07:56 Benzinga
Novan (NASDAQ: NOVN ) reported its Q2 earnings results on Thursday, August 11, 2022 at 07:00 AM. Here''s what investors need to know about the announcement. Earnings Novan beat estimated earnings by 22.81%, reporting an EPS of $-0.44 versus an … Full story available on Benzinga.com
Novan GAAP EPS of -$0.44 beats by $0.15, revenue of $6.16M misses by $0.44M 2022/08/11 10:37:06 Seeking Alpha
Novan press release (NOVN): Q2 GAAP EPS of -$0.44 beats by $0.15.Revenue of $6.16M (+721.3% Y/Y) misses by $0.44M.As of June 30, 2022, Novan had a total cash and cash…
Novan Reports Second Quarter 2022 Financial Results and Provides Corporate Update 2022/08/11 10:30:00 GlobeNewswire
– Total revenue of $6.2 million for the second quarter 2022 –
Earnings Scheduled For August 11, 2022 2022/08/11 09:09:16 Benzinga
Companies Reporting Before The Bell • Magic Software (NASDAQ: MGIC ) is projected to report quarterly earnings at $0.27 per share on revenue of $131.70 million. • Dingdong (Cayman) (NYSE: DDL ) is likely to report earnings for its second quarter. • Evelo Biosciences (NASDAQ: EVLO ) is projected to report earnings for its second quarter. • Affimed (NASDAQ: AFMD ) is estimated to report quarterly loss at $0.17 per share on revenue of $8.67 million. • CorEnergy Infr Trust (NYSE: CORR ) is expected to report earnings for its second quarter. • Six Flags Entertainment (NYSE: SIX ) is expected to report earnings for its second quarter. • Where Food Comes From (NASDAQ: WFCF ) is projected to report earnings for its second quarter. • BurgerFi International (NASDAQ: BFI ) is estimated to report earnings for its second quarter. • Smith-Midland (NASDAQ: SMID ) is expected to report earnings for its second quarter. • Kala Pharmaceuticals (NASDAQ: KALA ) is expected to report earnings for its second quarter.
JTC Team to Host Virtual Investor Innovation in Dermatology Spotlight Event Featuring Novan, Inc. 2022/04/25 14:00:00 Wallstreet:Online
- Live video webcast event with members of Novan, Inc. management on Tuesday, April 26th at 2:00 PM ET -FRENCHTOWN, NJ / ACCESSWIRE / April 25, 2022 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today …
Novan Inc. (NASDAQ: NOVN) Shares Have Been Down About -29.74% Year-To-Date Since The Beginning Of 2022 2022/04/23 17:00:00 Marketing Sentinel
During the last session, Novan Inc. (NASDAQ:NOVN)’s traded shares were 0.41 million, with the beta value of the company hitting 0.03. At the end of the trading day, the stock’s price was $2.93, reflecting an intraday loss of -1.68% or -$0.05. The 52-week high for the NOVN share is $20.74, that puts it down -607.85 … Novan Inc. (NASDAQ: NOVN) Shares Have Been Down About -29.74% Year-To-Date Since The Beginning Of 2022 Read More »
Novan to Participate in the Virtual Investor Innovation in Dermatology Spotlight Event 2022/04/20 13:05:00 GlobeNewswire
Live moderated video webcast with members of the Novan management team on Tuesday, April 26th at 2:00 PM ET Live moderated video webcast with members of the Novan management team on Tuesday, April 26th at 2:00 PM ET
2022 Women in Business Awards: Tomoko Maeda Chubachi – Novan 2022/03/25 03:00:00 Business Journals
Meet the winners in our 2022 Women in Business Awards!
2022 Women in Business Awards: Tomoko Maeda Chubachi – Novan 2022/03/25 03:00:00 Business Journals
Meet the winners in our 2022 Women in Business Awards!
Novan Announces Late-Breaking Abstract Accepted for Presentation at American Academy of Dermatology''s (AAD) 2022 Annual Meeting 2022/03/24 13:00:00 Benzinga
DURHAM, N.C., March 24, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ: NOVN ), today announced that data from its pivotal Phase 3 study of berdazimer gel 10.3% (SB206) for the treatment of molluscum contagiosum was selected for an oral presentation at a late-breaker session at the American Academy of Dermatology''s (AAD) 2022 Annual Meeting. Details of the abstract presentation are as follows: Title: Berdazimer 10.3% Gel (SB206): A Novel, Topical Nitric Oxide Releasing Medication: Results from a Pivotal Phase 3 Study in Patients (Children and Adults) with Molluscum Contagiosum Session: Clinical Studies/Pediatric Date & Time: March 26, 2022, at 10:20am ET Location: Rm. 253A The presentation will be given by Dr. John Browning M.D., F.A.A.D, F.A.A.P., MBA, Adjunct Associate Professor of Pediatrics and Dermatology at UT Health San Antonio and Baylor College of Medicine, and a Principal Investigator in the B-SIMPLE4 study. "We are pleased to present the compelling data from our Phase 3 study, BSIMPLE-4, at this prestigious dermatology event.
Novan Acquires EPI Health To Bolster Commercial Force For Potential Marketing Of Its lead Products 2022/03/11 16:10:27 Benzinga
Novan Inc (NASDAQ: NOVN ) has acquired EPI Health LLC , a specialty pharmaceutical company focused on the U.S. dermatology market. EPI Health offers a product portfolio that includes four prescription products across psoriasis, rosacea, dermatosis, and acne, with a 2021 operating revenue of $17.6 million. Deal consideration of $27.5 million consists of $11.0 million in cash and $16.5 million in … Full story available on Benzinga.com